Conference Coverage

Dual kinase inhibitor performs well in its first safety, efficacy study for atopic dermatitis

Publish date: February 24, 2018

 

REPORTING FROM AAD 2018

SOURCE: Bissonnette R et al. AAD 2018, Abstract 6777

Pages

Recommended Reading

Very preterm birth is linked to reduced risk of eczema
MDedge Family Medicine
Systemic corticosteroids not recommended for long-term treatment of eczema
MDedge Family Medicine
Atopic march largely attributed to genetic factors
MDedge Family Medicine
Antihistamines still are prescribed inappropriately for atopic dermatitis
MDedge Family Medicine
Topical steroid reduces atopic dermatitis relapse in children
MDedge Family Medicine
VIDEO: Dupilumab or cyclosporine for treating atopic dermatitis?
MDedge Family Medicine
VIDEO: Off-label dupilumab finding a home in pediatric AD
MDedge Family Medicine
Upadacitinib calms itch, clears skin in moderate to severe atopic dermatitis
MDedge Family Medicine
Anti–IL-33 antibody stakes a first-in-class claim on moderate to severe atopic dermatitis
MDedge Family Medicine
VIDEO: With new therapies available, it’s the ‘decade of eczema,’ researcher says
MDedge Family Medicine